News Release

应激激素可唤醒睡眠中的肿瘤细胞,增加癌症复发的风险

Peer-Reviewed Publication

American Association for the Advancement of Science (AAAS)

Stress Hormones Can Reawaken Sleeping Tumor Cells, Raising Risk of Cancer Recurrence (1 of 1)

video: Author-explainer video to summarize the major findings in "Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils." This material relates to a paper that appeared in the Dec. 2, 2020, issue of <i>Science Translational Medicine</i>, published by AAAS. The paper, by M. Perego at Wistar Institute in Philadelphia, PA; and colleagues was titled, "Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils." view more 

Credit: [Credit: The Wistar Institute]

一项对小鼠和来自80位肺癌患者的数据的研究表明,应激激素和被称为中性粒细胞的免疫细胞可能会通过唤醒休眠癌细胞而促使肿瘤在治疗多年后复发。这些实验可帮助回答一个长期存在的问题:癌症为什么会在看似被化疗或手术治愈后很长时间后再次发作;这些结果还提示,用已经批准的被称作β-受体阻滞剂的药物来靶向抑制应激激素或能帮助阻止肿瘤复发。肿瘤复发是癌症患者死亡的最重要原因之一,但究竟是什么生物学机制促使肿瘤复发则尚不清楚。但是,研究表明,肿瘤的复发是由休眠肿瘤细胞再次变得活跃而展现的;这些休眠肿瘤细胞最初是在癌症早期扩散的。Michela Perego和同事发现,诸如去甲肾上腺素等应激激素会重新激活小鼠体内休眠状态的肺癌和卵巢癌细胞。具体而言,科学家们发现,小鼠处于应激状态会增加其应激激素水平,它们可导致中性粒细胞释放S100A8 / A9蛋白和脂肪分子,后者会进而促使肿瘤细胞从休眠状态中复苏。然而,在接受某实验性β受体阻滞剂的承受巨大压力的小鼠体内,肿瘤细胞则仍会处于休眠状态。该团队还研究了80例手术切除了肺癌的患者的血清样本,发现那些S100A8 / A9浓度较高的患者会在术后33个月内更有可能癌症复发。Perego等人说,以S100A8 / A9蛋白作为标靶的β受体阻滞剂或化合物应作为可能中断再激活过程的疗法进行评估;但他们强调,需要有更精细的肿瘤细胞休眠模型。

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.